Efficacy and Safety of Ideglira in Older Patients with Type 2 Diabetes
| Autor: | Kristina Ranc, Ildiko Lingvay, Yehuda Handelsman, Andreas Liebl, Sultan Linjawi, Natalie Halladin, Tina Vilsbøll |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Blood Glucose
Insulin degludec medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Glargine 030209 endocrinology & metabolism Type 2 diabetes 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Diabetes mellitus Humans Hypoglycemic Agents Medicine 030212 general & internal medicine Aged Glycemic Glycated Hemoglobin business.industry Liraglutide Insulin glargine Insulin General Medicine medicine.disease Confidence interval Insulin Long-Acting Drug Combinations Diabetes Mellitus Type 2 business medicine.drug |
| Zdroj: | Endocrine Practice. 25:144-155 |
| ISSN: | 1530-891X |
| DOI: | 10.4158/ep-2018-0284 |
| Popis: | The efficacy and safety of insulin degludec/liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years.A post hoc analysis compared results of patients aged ≥65 versus65 years from DUAL II, III, and V. These were 26-week, phase 3, randomized, twoarm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents. We evaluated 311 patients aged65 and 87 patients aged ≥65 years from DUAL II, 326 patients65 years and 112 patients ≥65 years from DUAL III, and 412 patients65 years and 145 patients ≥65 years from DUAL V. Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).In patients ≥65 years, hemoglobin A1C decreased to a greater extent with IDegLira than with comparators (estimated treatment differences, -1.0% [-1.5; -0.6]Patients aged ≥65 years on basal insulin or GLP-1RA can improve glycemic control with IDegLira, and it is well tolerated overall.A1C = hemoglobin A1C; AE = adverse event; CI = confidence interval; Degludec = insulin degludec; EOT = end of trial; ETD = estimated treatment difference; FPG = fasting plasma glucose; GLP-1RA = glucagon-like peptide 1 receptor agonist; IDegLira = insulin degludec/liraglutide; IGlar U100 = insulin glargine 100 U/mL; SU = sulfonylurea; T2D = type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|